Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ingevity (NGVT) Assets (2016 - 2025)

Historic Assets for Ingevity (NGVT) over the last 11 years, with Q3 2025 value amounting to $1.8 billion.

  • Ingevity's Assets fell 1708.27% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 1708.27%. This contributed to the annual value of $2.0 billion for FY2024, which is 2289.86% down from last year.
  • Ingevity's Assets amounted to $1.8 billion in Q3 2025, which was down 1708.27% from $1.9 billion recorded in Q2 2025.
  • In the past 5 years, Ingevity's Assets ranged from a high of $2.8 billion in Q2 2023 and a low of $1.8 billion during Q3 2025
  • In the last 5 years, Ingevity's Assets had a median value of $2.4 billion in 2021 and averaged $2.4 billion.
  • As far as peak fluctuations go, Ingevity's Assets skyrocketed by 1953.93% in 2023, and later plummeted by 2289.86% in 2024.
  • Quarter analysis of 5 years shows Ingevity's Assets stood at $2.5 billion in 2021, then grew by 10.83% to $2.7 billion in 2022, then decreased by 4.14% to $2.6 billion in 2023, then fell by 22.9% to $2.0 billion in 2024, then fell by 9.33% to $1.8 billion in 2025.
  • Its Assets was $1.8 billion in Q3 2025, compared to $1.9 billion in Q2 2025 and $2.1 billion in Q1 2025.